The assay aims to find chemical probes for 2HG-producing tumor cells by performing a synthetic lethal screen using paired cell lines that either overproduce 2HG or have IDH1 expression knocked-down. The qHTS results presented in the data are for the HT-1080-NT fibrosarcoma cell line. Recurrent IDH mutations in up to 70% of secondary gliomas and 10% of AML cases were also identified, with the somatic mutation resulting in a loss-of-function in metabolizing isocitrate but a gain-of-function to produce the oncometabolite 2HG, defining IDH1 as an oncogene and providing an opportunity for new therapies for glioma and AML patients. Is the molecule effective to this assay?